Human graft-derived mesenchymal stromal cells potently suppress alloreactive T-cell responses

Stem Cells and Development

Volumn 24, Issue 12, 2015, Pages 1436-1447

  De Mare Bredemeijer, Emmy L D ^a   Mancham, Shanta ^a   Verstegen, Monique M A ^a   De Ruiter, Petra E ^a   Van Gent, Rogier ^a   O'Neill, David ^b   Tilanus, Hugo W ^a   Metselaar, Herold J ^a   De Jonge, Jeroen ^a   Kwekkeboom, Jaap ^a   Hall, Sean R R ^a,c   Van Der Laan, Luc J W ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b Caladrius Biosciences   (United States)

^c UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; INDOLEAMINE 2,3 DIOXYGENASE; CD274 PROTEIN, HUMAN; PROGRAMMED DEATH 1 LIGAND 1;

ALLOIMMUNITY; ARTICLE; CELL POPULATION; CELL PROLIFERATION; CONTROLLED STUDY; DEGRANULATION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOPHENOTYPING; INTERFERON PRODUCTION; LIVER GRAFT; MESENCHYMAL STROMA CELL; PRIORITY JOURNAL; T LYMPHOCYTE; ADVERSE EFFECTS; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; CELL DIFFERENTIATION; CYTOLOGY; GENETICS; GRAFT REJECTION; IMMUNOLOGY; LIVER TRANSPLANTATION; LYMPHOCYTE ACTIVATION; MESENCHYMAL STEM CELL TRANSPLANTATION; METABOLISM; PATHOLOGY;

ANTIGENS, CD274; CELL DIFFERENTIATION; CELL PROLIFERATION; GRAFT REJECTION; HUMANS; IMMUNOPHENOTYPING; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; INTERFERON-GAMMA; LIVER TRANSPLANTATION; LYMPHOCYTE ACTIVATION; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; T-LYMPHOCYTES;

EID: 84930448863     PISSN: 15473287     EISSN: 15578534     Source Type: Journal    
DOI: 10.1089/scd.2014.0485     Document Type: Article

References (41)

1. Friedenstein AJ, RK Chailakhyan, NV Latsinik, AF Panasyuk and IV Keiliss-Borok. (1974). Stromal cells responsible for transferring the microenvironment of the hemopoietic tissues. Cloning in vitro and retransplantation in vivo. Transplantation 17:331-340.
2. Friedenstein AJ, AA Ivanov-Smolenski, RK Chajlakjan, UF Gorskaya, AI Kuralesova, NW Latzinik and UW Gerasimow. (1978). Origin of bone marrow stromal mechanocytes in radiochimeras and heterotopic transplants. Exp Hematol 6:440-444.
3. Pittenger MF, AM Mackay, SC Beck, RK Jaiswal, R Douglas, JD Mosca, MA Moorman, DW Simonetti, S Craig and DR Marshak. (1999). Multilineage potential of adult human mesenchymal stem cells. Science 284:143-147.
4. Crisan M, S Yap, L Casteilla, CW Chen, M Corselli, TS Park, G Andriolo, B Sun, B Zheng, et al. (2008). A perivascular origin for mesenchymal stem cells in multiple human organs. Cell Stem Cell 3:301-313.
5. Murray IR, CC West, WR Hardy, AW James, TS Park, A Nguyen, T Tawonsawatruk, L Lazzari, C Soo and B Peault. (2013). Natural history of mesenchymal stem cells, from vessel walls to culture vessels. Cell Mol Life Sci 71:1353-1374.
6. Keating A. (2012). Mesenchymal stromal cells: new directions. Cell Stem Cell 10:709-716.
7. Tolar J, K Le Blanc, A Keating and BR Blazar. (2010). Concise review: hitting the right spot with mesenchymal stromal cells. Stem Cells 28:1446-1455.
8. Uccelli A, L Moretta and V Pistoia. (2008). Mesenchymal stem cells in health and disease. Nat Rev Immunol 8:726-736.
9. Aggarwal S and MF Pittenger. (2005). Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 105:1815-1822.
10. Le Blanc K, I Rasmusson, B Sundberg, C Gotherstrom, M Hassan, M Uzunel and O Ringden. (2004). Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet 363:1439-1441.
11. Nauta AJ and WE Fibbe. (2007). Immunomodulatory properties of mesenchymal stromal cells. Blood 110:3499-3506.
12. De Miguel MP, S Fuentes-Julian, A Blazquez-Martinez, CY Pascual, MA Aller, J Arias and F Arnalich-Montiel. (2012). Immunosuppressive properties of mesenchymal stem cells: advances and applications. Curr Mol Med 12: 574-591.
13. da Silva Meirelles L, PC Chagastelles and NB Nardi. (2006). Mesenchymal stem cells reside in virtually all postnatal organs and tissues. J Cell Sci 119(Pt 11):2204-2213.
14. Pan Q, SM Fouraschen, FS Kaya, MM Verstegen, M Pescatori, AP Stubbs, W van Ijcken, A van der Sloot, R Smits, et al. (2011). Mobilization of hepatic mesenchymal stem cells from human liver grafts. Liver Transpl 17:596-609.
15. Bernardo ME and WE Fibbe. (2013). Mesenchymal stromal cells: sensors and switchers of inflammation. Cell Stem Cell 13:392-402.
16. Kaipe H, T Erkers, B Sadeghi and O Ringden. (2014). Stromal cells-are they really useful for GVHD? Bone Marrow Transplant 49:737-743.
17. Calne RY, RA Sells, JR Pena, DR Davis, PR Millard, BM Herbertson, RM Binns and DA Davies. (1969). Induction of immunological tolerance by porcine liver allografts. Nature 223:472-476.
18. Diehl L, A Schurich, R Grochtmann, S Hegenbarth, L Chen and PA Knolle. (2008). Tolerogenic maturation of liver sinusoidal endothelial cells promotes B7-homolog 1-dependent CD8+ T cell tolerance. Hepatology 47:296-305.
19. Thomson AW and PA Knolle. (2010). Antigen-presenting cell function in the tolerogenic liver environment. Nat Rev Immunol 10:753-766.
20. Clavien PA, PR Harvey and SM Strasberg. (1992). Preservation and reperfusion injuries in liver allografts. An overview and synthesis of current studies. Transplantation 53:957-978.
21. Goode HF, NR Webster, PD Howdle, JP Leek, JP Lodge, SA Sadek and BE Walker. (1994). Reperfusion injury, antioxidants and hemodynamics during orthotopic liver transplantation. Hepatology 19:354-359.
22. Ishida Y, Y Agata, K Shibahara and T Honjo. (1992). Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J 11:3887-3895.
23. Freeman GJ, AJ Long, Y Iwai, K Bourque, T Chernova, H Nishimura, LJ Fitz, N Malenkovich, T Okazaki, et al. (2000). Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 192:1027-1034.
24. LaGier AJ and JS Pober. (2006). Immune accessory functions of human endothelial cells are modulated by overexpression of B7-H1 (PDL1). Hum Immunol 67:568-578.
25. Croitoru-Lamoury J, FM Lamoury, M Caristo, K Suzuki, D Walker, O Takikawa, R Taylor and BJ Brew. (2011). Interferon-gamma regulates the proliferation and differentiation of mesenchymal stem cells via activation of indoleamine 2,3 dioxygenase (IDO). PLoS One 6:e14698.
26. Francois M, R Romieu-Mourez, M Li and J Galipeau. (2012). Human MSC suppression correlates with cytokine induction of indoleamine 2,3-dioxygenase and bystander M2 macrophage differentiation. Mol Ther 20:187-195.
27. Di Nicola M, C Carlo-Stella, M Magni, M Milanesi, PD Longoni, P Matteucci, S Grisanti and AM Gianni. (2002). Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood 99:3838-3843.
28. Hall SR, Y Jiang, E Leary, G Yavanian, S Eminli, DW O'Neill and WA Marasco. (2013). Identification and isolation of small CD44-negative mesenchymal stem/progenitor cells from human bone marrow using elutriation and polychromatic flow cytometry. Stem Cells Transl Med 2: 567-578.
29. Tapirdamaz O, S Mancham, LJ van der Laan, G Kazemier, K Thielemans, HJ Metselaar and J Kwekkeboom. (2010). Detailed kinetics of the direct allo-response in human liver transplant recipients: new insights from an optimized assay. PloS One 5:e14452.
30. Hoogduijn MJ, MM Verstegen, AU Engela, SS Korevaar, M Roemeling-van Rhijn, A Merino, M Franquesa, J de Jonge, JN Ijzermans, et al. (2014). No evidence for circulating mesenchymal stem cells in patients with organ injury. Stem Cells Dev 23:2328-2335.
31. Yang J, LV Riella, S Chock, T Liu, X Zhao, X Yuan, AM Paterson, T Watanabe, V Vanguri, et al. (2011). The novel costimulatory programmed death ligand 1/B7.1 pathway is functional in inhibiting alloimmune responses in vivo. J Immunol 187:1113-1119.
32. Bos CL, DJ Richel, T Ritsema, MP Peppelenbosch and HH Versteeg. (2004). Prostanoids and prostanoid receptors in signal transduction. Int J Biochem Cell Biol 36:1187-1205.
33. Jassem W, DD Koo, L Cerundolo, M Rela, ND Heaton and SV Fuggle. (2003). Leukocyte infiltration and inflammatory antigen expression in cadaveric and living-donor livers before transplant. Transplantation 75:2001-2007.
34. Jassem W, DD Koo, P Muiesan, L Cerundolo, M Rela, SV Fuggle and ND Heaton. (2003). Non-heart-beating versus cadaveric and living-donor livers: differences in inflammatory markers before transplantation. Transplantation 75: 1386-1390.
35. Yang SH, MJ Park, IH Yoon, SY Kim, SH Hong, JY Shin, HY Nam, YH Kim, B Kim and CG Park. (2009). Soluble mediators from mesenchymal stem cells suppress T cell proliferation by inducing IL-10. Exp Mol Med 41:315-324.
36. Nauta AJ, AB Kruisselbrink, E Lurvink, R Willemze and WE Fibbe. (2006). Mesenchymal stem cells inhibit generation and function of both CD34 +-derived and monocytederived dendritic cells. J Immunol 177:2080-2087.
37. Chinnadurai R, IB Copland, SR Patel and J Galipeau. (2014). IDO-independent suppression of T cell effector function by IFN-gamma-licensed human mesenchymal stromal cells. J Immunol 192:1491-1501.
38. Wang Y, X Chen, W Cao and Y Shi. (2014). Plasticity of mesenchymal stem cells in immunomodulation: pathological and therapeutic implications. Nat Immunol 15: 1009-1016.
39. Le Blanc K and O Ringden. (2007). Immunomodulation by mesenchymal stem cells and clinical experience. J Intern Med 262:509-525.
40. Peng L, DY Xie, BL Lin, J Liu, HP Zhu, C Xie, YB Zheng and ZL Gao. (2011). Autologous bone marrow mesenchymal stem cell transplantation in liver failure patients caused by hepatitis B: short-term and long-term outcomes. Hepatology 54:820-828.
41. Shi M, Z Zhang, R Xu, H Lin, J Fu, Z Zou, A Zhang, J Shi, L Chen, et al. (2012). Human mesenchymal stem cell transfusion is safe and improves liver function in acute-onchronic liver failure patients. Stem Cells Transl Med 1:725-731.